Infinity Pharmaceuticals Announces the Date of Its Third Quarter 2022 Financial Results Conference Call and Webcast
November 07 2022 - 8:25AM
Business Wire
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage
biotechnology company developing eganelisib, a first-in-class,
oral, immuno-oncology macrophage reprogramming therapeutic, will
host a conference call on Monday, November 14, 2022, at 8:30 AM ET
to report its financial results for the third quarter of 2022.
To access the conference call, please register at
https://register.vevent.com/register/BId44f86e6a2af42faadbb2844131346a8.
Upon registering, each participant will be provided with call
details and access codes. All participants are encouraged to join
10 minutes prior to the start time. A live webcast of the
conference call can be accessed from the Events & Presentations
page in the Investors/Media section of Infinity’s website at
www.infi.com. An archived version of the webcast will be available
on Infinity's website for 30 days following the event.
About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is
a clinical-stage biotechnology company developing eganelisib
(IPI-549), a first-in-class, oral, immuno-oncology macrophage
reprogramming therapeutic which is designed to address a
fundamental biologic mechanism of immune suppression in cancer in
multiple clinical studies. MARIO-3 is the first eganelisib
combination study in front-line advanced cancer patients and is
evaluating eganelisib in combination with Tecentriq® and Abraxane®
in front-line TNBC and in combination with Tecentriq and Avastin®
in front-line RCC. MARIO-275 is a randomized, controlled
combination study of eganelisib combined with Opdivo® in I/O naïve
urothelial cancer. For more information on Infinity, please refer
to Infinity's website at www.infi.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221107005313/en/
Investor Relations: Kevin Lui Real Chemistry
klui@realchemistry.com
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From Apr 2024 to May 2024
Infinity Pharmaceuticals (NASDAQ:INFI)
Historical Stock Chart
From May 2023 to May 2024